Cheng Jing, Cai Huanghao, Jia Tianrong, Ding Yihan, reporter of the Oriental Network, Zhongxiang News Reporter
On October 30, the third session of the World's Top Scientists Forum was held in Shanghai, and Xie Xiaoliang, winner of the 2015 Albany Medical Prize and an academician of the American Academy of Sciences, said that neutralizing antibodies provide hope for a cure for new crown pneumonia, after Trump had accepted neutralizing antibody therapy, but for pharmaceutical companies, such a therapeutic dose is very large, "too expensive" to be provided to the general public.
Xie Xiaoliang pointed out that with the approaching of winter, the global new crown cases continue to hit a new high, the new new crown pneumonia patients are in great need of effective drug treatment, there is no specific drug for the new crown pneumonia, neutralizing antibodies provide hope for the cure of new crown pneumonia.
It is reported that neutralizing antibody therapy is plasma therapy with the blood of a rehabilitated patient, such a therapy has been proven to be effective, but the supply is limited, and a patient needs 1200 ml of blood from a recovered patient to carry out such treatment. The active ingredient in plasma therapy is the neutralizing antibody produced by the human immune system.
Xie Xiaoliang introduced that after US President Trump announced the confirmed infection with the new crown virus, he received neutralizing antibody therapy. After Trump was admitted to the hospital, he was injected with regen-cov2, an antibody combination therapy drug developed by 8 grams of regeneration yuan (regeneron).
Xie Xiaoliang pointed out that 8 grams of neutralizing antibody drugs are "very large quantities", in fact, only 2 grams can achieve the same effect, but even 2 grams is "a very large amount", which is too expensive for pharmaceutical companies to supply to the general public, so it is still necessary to develop more powerful neutralizing antibody treatments.
The results of the regin-cov2 clinical trial released by Regeneration Yuan on September 30 showed that for patients with low serum antiviral antibody concentrations, regn-cov2 cocktail therapy can reduce the number of viruses and reduce the time to symptoms in non-hospitalized patients, in addition to showing a positive trend that can reduce the number of patient visits.
Earlier this month, Regeneration Issued a statement announcing that it had submitted an emergency use authorization application for regn-cov2 treatment of patients with new coronavirus pneumonia to the US Food and Drug Administration (FDA).
Regeneration Yuan CEO Schlever said on the 11th of this month that the U.S. government has spent $450 million to order 300,000 doses of regin-cov2 neutralizing antibody drugs and will provide them to people free of charge. The company has produced 50,000 doses, but "this is far from enough", and if the therapy is eventually proven to be effective, it will require the participation of other pharmaceutical companies in production.
At present, a number of new crown neutralizing antibodies around the world are still in clinical trials. Xie Xiaoliang said in a previous interview that only science can stop the epidemic and save mankind from disaster, "I look forward to the advent of the new crown special drug can truly alleviate this crisis and test for all mankind." ”